{{Rsnum
|rsid=3846663
|Gene=HMGCR
|Chromosome=5
|position=75359901
|Orientation=plus
|GMAF=0.3976
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=HMGCR
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 38.1 | 45.1 | 16.8
| HCB | 21.2 | 49.6 | 29.2
| JPT | 16.8 | 58.4 | 24.8
| YRI | 68.0 | 27.9 | 4.1
| ASW | 66.7 | 24.6 | 8.8
| CHB | 21.2 | 49.6 | 29.2
| CHD | 21.1 | 46.8 | 32.1
| GIH | 12.9 | 53.5 | 33.7
| LWK | 45.5 | 48.2 | 6.4
| MEX | 53.4 | 32.8 | 13.8
| MKK | 57.1 | 37.2 | 5.8
| TSI | 39.2 | 44.1 | 16.7
| HapMapRevision=28
}}{{PMID Auto GWAS
|PMID=19060906
|Trait=LDL cholesterol
|Title=Common variants at 30 loci contribute to polygenic dyslipidemia
|RiskAllele=T
|Pval=8E-12
|OR=0.07
|ORtxt=[0.03-0.11] SD increase
|OA=1
}}

[[LDL cholesterol]] levels being the quantitative trait associated with in {{PMID|19197348|OA=1
}}

{{PMID Auto GWAS
|PMID=19197348
|Trait=Quantitative traits
|Title=Genome-wide association studies in an isolated founder population from the Pacific Island of Kosrae
|RiskAllele=T
|Pval=0.000001
|OR=0.21
|ORtxt=[NR] mg/dL increase
|OA=1
}}

{{PharmGKB
|RSID=rs3846663
|Name_s=
|Gene_s=HMGCR
|Feature=Intron
|Evidence=PubMed ID:19060906; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: Common variants at 30 loci contribute to polygenic dyslipidemia. (Initial Sample Size: 19,840 individuals; Replication Sample Size: Up to 20,623 individuals); (Region: 5q13.3; Reported Gene(s): HMGCR; Risk Allele: rs3846663-T); (p-value= 0.000000000008).This variant is associated with LDL cholesterol.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA164740249
}}

{{PMID|18802019|OA=1
}} Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13.

{{PMID|19554360|OA=1
}} The HMG-CoA reductase gene and lipid and lipoprotein levels: the multi-ethnic study of atherosclerosis.

{{PMID|19951432|OA=1
}} Analysis of recently identified dyslipidemia alleles reveals two loci that contribute to risk for carotid artery disease.

{{PMID|20005478|OA=1
}} The role of HMGCR alternative splicing in statin efficacy.

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs3846663
|overall_frequency_n=47
|overall_frequency_d=128
|overall_frequency=0.367188
|n_genomes=35
|n_genomes_annotated=0
|n_haplomes=43
|n_articles=0
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | Illumina Human 1M}}